Evidence map›Paper›PMID 41649174›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Strawberry Notch 1 Acts as a Transcriptional Regulator Driving Oncogenic Programs in Liver Carcinogenesis.

Sarah Fritzsche, Raisatun Nisa Sugiyanto, Kira Gür, Alina Krumme, Maxime Le Marois, Angelika Fraas, Aslihan Inal, Mario Huerta, Vanessa Henriques, Eva Eiteneuer and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Sarah FritzscheInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Raisatun Nisa SugiyantoInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Kira GürInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Alina KrummeInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Maxime Le MaroisInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Angelika FraasInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Aslihan InalInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Mario HuertaInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Vanessa HenriquesInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Eva EiteneuerInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Thomas AlbrechtInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Alphonse CharbelInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Michael T DillDepartment of Gastroenterology, Hepatology, Infectious Diseases and Intoxications, Heidelberg University Hospital, Heidelberg, Germany.
Carsten StichtNGS Core Facility, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Carolina De La TorreNGS Core Facility, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Stefan PuschDepartment of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.
Arianeb MehrabiLiver Cancer Center Heidelberg (LCCH), Heidelberg, Germany.
Kai BreuhahnInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Junfang JiThe MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, and Innovation Center for Cell Signaling Network, Life Sciences Institute, Zhejiang University, Hangzhou, China.
Peter SchirmacherInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Benjamin GoeppertInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.
Stephanie RoesslerInstitute of Pathology, University Hospital Heidelberg, Medical Faculty, Heidelberg University, Heidelberg, Germany.ORCID https://orcid.org/0000-0002-5333-5942

Funding

Deutsche Krebshilfe 70113922German Research Foundation 314905040German Research Foundation 469332207German Research Foundation 493697503German Research Foundation INST35/1503-1FUGGMinistry of Science, Research and the Arts Baden-Württemberg
6 · The paper itself

Abstract

Aberrant Notch signaling has been identified as a key driver of cancer development. Genetic studies in Drosophila showed that the knockout of strawberry notch (sno) mimics the loss of notch. Here, we found that Strawberry Notch 1 (SBNO1) is upregulated in several cancer entities and elucidated the role of SBNO1 in liver cancer development. In hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), SBNO1 protein was significantly increased and localized to the nucleus suggesting its involvement in gene regulation. SBNO1-inhibition reduced cell viability, colony formation and migration and induced distinct expression patterns in HCC and CCA cell lines. However, BioID revealed that SBNO1 similarly modulates gene regulation in HCC and CCA by binding to general transcription factors TAF4 and TAF3. Deletion of Sbno1 in murine liver cancer cells Hep55.1C reduced tumor growth in vivo. In addition, inhibition of Sbno1 significantly reduced liver tumor development in three different mouse models of HCC and CCA. Furthermore, Sbno1-deletion reduced biliary differentiation and angiogenesis in the tumor margin, underscoring the necessity of Sbno1 in Notch-driven CCA formation. Thus, we identified SBNO1 as a transcriptional regulator required for liver cancer development and progression.

Indexed as

CarcinogenesisCarcinoma, HepatocellularCholangiocarcinomaLiver NeoplasmsReceptor, Notch1AnimalsCell Line, TumorGene Expression Regulation, NeoplasticHumansMiceSignal TransductionReceptor, Notch1cancercholangiocarcinomahepatocellular carcinomanotch signalingSBNO1

Identifiers

PMID41649174
PMCPMC13067845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.